Ideaya Biosciences, Inc. progresses trials for uveal melanoma and solid tumors, with key upcoming data milestones. Click for ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis as a treatment for a type of lung cancer. The US regulator cleared ...

The African Democratic Congress (ADC) said it has undertook bold step towards repositioning itself as a leading political force ahead of the 2027 general elections, declaring itself the coalition ...

The National Chairman of the African Democratic Congress, Ralph Nwosu, has announced ADC as Nigeria’s coalition party in preparation for the 2027 election. Nwosu also voiced his worries about ...

That study established the company’s Astellas-partnered Nectin-4 ADC Padcev and Merck & Co.’s PD-1 king Keytruda as the standard first-line bladder cancer treatment in a biomarker-unselective ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate after taking a look at the early-stage data. The asset in question ...

The African Democratic Congress (ADC) has criticized the ruling All Progressives Congress (APC) for leading Nigeria into unprecedented economic decline since it took power in 2015. Dr. Mani Ahmed ...

LAUSANNE, Switzerland, April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ...

Keymed Biosciences Inc., a biotech company focused on the urgent unmet clinical needs, announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational ...

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.36, expectations were $-0.38. Operator: Good morning, ladies and gentlemen, and welcome to ADC Therapeutics’ First Quarter ...

SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...